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This article is part of a series of reviews
covering The Cytoskeleton appearing in
Volume 256 of Immunological Reviews.
Summary: The importance of the cytoskeleton in mounting a success-
ful immune response is evident from the wide range of defects that
occur in actin-related primary immunodeficiencies (PIDs). Studies of
these PIDs have revealed a pivotal role for the actin cytoskeleton in
almost all stages of immune system function, from hematopoiesis and
immune cell development, through to recruitment, migration, intercel-
lular and intracellular signaling, and activation of both innate and
adaptive immune responses. The major focus of this review is the
immune defects that result from mutations in the Wiskott-Aldrich syn-
drome gene (WAS), which have a broad impact on many different pro-
cesses and give rise to clinically heterogeneous immunodeficiencies.
We also discuss other related genetic defects and the possibility of
identifying new genetic causes of cytoskeletal immunodeficiency.
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The actin cytoskeleton
The actin cytoskeleton is composed of a network of actin
filaments that are polymerized from actin monomers. Poly-
merization is initiated by three classes of actin nucleators,
the Arp2/3 complex, the formin family, and the more
recently identified Spire, cordon-bleu, and leiomodin family
(reviewed in 1). Each class of nucleators has a distinct
mechanism for initiating actin polymerization. The first actin
nucleator to be identified was the Arp2/3 complex (2–4).
This complex is unique among all actin nucleators in its
ability to form branched actin networks, and its activity is
regulated by the eight members of the Wiskott-Aldrich
syndrome protein (WASp) family. The next family of actin
nucleators identified was the formins, with at least 15 mam-
malian formins described, and the final family of actin nu-
cleators is the spire, cordon-bleu, and leiomodin family.
Nucleation is just one aspect of actin cytoskeletal regulation.
Each new actin filament may then be elongated, capped,
severed, depolymerized, bundled or crosslinked by actin-
binding proteins, and driven by motor proteins such as
myosin II (reviewed in 5).
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The actin cytoskeleton forms the basis of the cell cortex,
onto which the cell membrane is attached and within which
microtubules and intermediate filaments form a network
that organizes internal cell structure. Restructuring the
cytoskeleton allows cells to rapidly change their shape in a
timescale of seconds (reviewed in 6). Given that the actin
cytoskeleton provides mechanical support for the cell and is
the main determinate of cellular rheology (7), the network
is surprisingly dynamic, with actin turnover occurring with
a half-life as short as 15 s (8). Other components of the
actin cortex are even more dynamic; the muscle in the sys-
tem, myosin II, can turn over in under 10 s (9, 10), while
some of the proteins that crosslink actin filaments may turn
over as rapidly as every second (11). The actin cytoskeleton
is a complex system that provides a structure that delivers
robust mechanical support yet is sufficiently dynamic to
drive cellular morphogenesis. Maintaining this multifaceted
functionality requires the regulated interaction of over 100
associated proteins (5).
Cytoskeletal rearrangement generates the driving force for
morphogenesis that is essential for cell functions such as mito-
sis and cytokinesis, cell migration, and intercellular interac-
tions. These processes are central to the development and
function of many cell types, tissues, and organs. The critical
role of the actin cytoskeleton is evident from the profound
impact mutations of actin regulatory proteins have on devel-
opment, with loss of function of many of these genes result-
ing in a lethal phenotype. Indeed, if we take actin polymer
nucleation as an example, we find that very few of these genes
are dispensable in normal development. Loss of Arp2/3 func-
tion through knockout of ARPC3 is embryonic lethal (12). Dis-
ruption of the WASp family of Arp2/3 activators is similarly
catastrophic: loss of N-WASp, Wave2, and Wash are all
embryonic lethal (13–15), and WAVE1 knockout results in
severe neurological defects (16). Loss of the formins Fmn2 or
Fhod3 is lethal (17, 18), and knockout of other formins, such
as Fmn1, result in severe developmental abnormalities (19).
The final class of actin nucleators, the WH2-containing pro-
teins, again show severe consequences when their function is
lost, with knockout of Spire1 or Spire2 individually showing
no phenotype but double knockout resulting in meiosis fail-
ure (20).
Actin cytoskeletal defects as a cause of
immunodeficiency
Given the indispensable nature of the actin cytoskeleton, it
is perhaps surprising that cytoskeletal defects exist that can
cause immunodeficiency without having a far wider impact
on development. However, a small number of actin regula-
tory proteins function solely or primarily in cells of the
immune system, and mutation of these genes gives rise to a
distinct subset of primary immunodeficiencies (PIDs).
Defects in immune function that result from actin cytoskele-
tal defects encompass nearly every stage of the immune
response: proliferation of hematopoietic cells in the bone
marrow, migration, and cellular interactions needed to
develop into mature effector cells, trans-migration through
the endothelium to the sight of infection, dramatic shape
change needed to phagocytose invading pathogens, internal-
ization and presentation of antigens, and the intimate cellu-
lar interactions needed for direct cell to cell signaling. The
first described and most studied actin-related PID is WAS.
Through the study of this and other actin-related PIDs, we
have made substantial progress in our understanding of the
role of the actin cytoskeleton in functioning of the immune
system.
Genetic basis of Wiskott-Aldrich syndrome
WAS (recently reviewed in 21–24) was first described by
Alfred Wiskott in 1937 as a syndrome affecting three broth-
ers characterized by abnormally low numbers of small plate-
lets (microthrombocytopenia), bloody diarrhea, eczema,
recurrent fever, and ear infections. In 1954, Robert Aldrich
described a similar condition over six generations of a single
family that affected only men, clearly demonstrating X-
linked inheritance. The gene responsible was identified in
1994, located on the X-chromosome (25), and is the
founding member of the WASp family of Arp2/3 regula-
tors.
WASp family proteins
The WASp family regulates actin polymerization through
activation of the Arp2/3 complex. There are eight members
of this family: WASp; Neural WASp (N-WASp or Wiskott-
Aldrich syndrome like, WASL); the three WASp family
verprolin-homologous proteins (WAVE/SCAR/WASF 1, 2
and 3); WASp and SCAR homolog (WASH); WASp homolog
associated with actin, Golgi membranes, and microtubules
(WHAMM); and junction-mediating regulatory protein
(JMY). These proteins have no intrinsic catalytic activity and
act through a conserved C-terminal domain to activate the
ARP2/3 complex. Expression of WASp is restricted to the
hematopoietic system (25), WAVE1 and WAVE3 are
restricted to neural tissue (26), and the other WASp family
proteins are widely expressed (15, 26–29).
© 2013 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
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WASp structure and function
WASp is a multidomain protein that integrates signals from
a variety of intracellular signaling molecules to facilitate the
controlled activation of the Arp2/3 complex (Fig. 1). The
five domains of WASp are the N-terminal Ena-VASP homol-
ogy domain (EVH1), a basic domain, the GTPase binding
domain (GBD), the polyproline domain, and finally the
C-terminal verprolin homology (also known as Wasp
Homology 2) – central – and acidic regions that comprise
the VCA domain. WASp shares extensive homology with N-
WASp, with 46% identity and 72% homology at the amino
acid level and 80% identity in the functional domains. These
proteins can substitute for one another in many in vitro
assays, and biochemical analysis of WASp and N-WASp has
often been performed on N-WASp, with WASp function
extrapolated from these studies.
Cytosolic WASp is held in an auto-inhibited, inactive con-
formation through intramolecular tethering of the VCA
domain to the central GBD domain. At the cell membrane,
WASp is activated by releasing the VCA domain from this
inhibited conformation (Fig. 1). WASp activation has classi-
cally been described as relying on Cdc42, phosphatidylinosi-
tol 4,5-bisphosphate (PIP2) and tyrosine phosphorylation,
with additional input from a range of kinases, adapters and
actin-binding proteins(reviewed in 1, 22, 23). The combina-
tion of these inputs allows for multilevel regulation of
WASp, and our understanding of WASp regulation continues
to evolve. For example, recent studies have shown how the
physical micro-environment can influence WASp activity.
WASp dimerization induced by recruitment into large com-
plexes greatly enhances activity, and membrane curvature
allows a switch in the activating phosphoinositides from
PIP2 to phosphatidylinositol 4-phosphate PI(3)P (30, 31).
We are just beginning to understand some of the mecha-
nisms that control WASp inactivation and proteolysis,
revealing important roles for WASp stabilization by WIP
(32–35) and control of proteolysis by phosphorylation of
tyrosine 291. This phosphorylation appears to target WASp
for proteosomal and/or calpain-mediated degradation and is
important for podosome disassembly and regulation of
WASp activity in the IS in T cells (36–39). How Y291 phos-
phorylation regulates both activation and deactivation of
WASp is not fully determined, but one effect appears to be
recruitment of the E3 ligase Cbl-b, which contributes to
ubiquitination of specific sites in the WH1 domain leading
to degradation (37). So, tyrosine phosphorylation may con-
tribute both to activation of WASp and at the same time
make it susceptible to proteolytic destruction. This could
provide a control mechanism for temporal and spatial
limitation of actin polymerization.
WAS mutations
There are over 300 unique disease-causing mutations in
WAS (21, 40–42) that result in three distinct conditions,
classical WAS, X-linked thrombocytopenia (XLT), and X-
linked neutropenia (XLN). These 300 mutations are unlikely
to be an exhaustive list, as new disease-causing mutations
are regularly identified (43). The majority of WAS mutations
are in the EVH1 domain (40) and result in decreased affin-
ity for the WASp chaperone WIP and reduced WASp expres-
sion due to proteolysis (32–34, 44–46).
Classic WAS tends to result when the mutation leads to
near complete loss of WASp or expression of a truncated
protein. XLT is a milder form WAS and is often a result of
WAS mutations that allow residual although substantially
reduced WASp expression. Some mutations, however, may
allow expression of normal amounts of WASp that is
functionally defective, for example through disturbance of
Arp2/3 complex binding (A. J. Worth, unpublished data,
Austen Worth, personal communication). X-linked neutro-
Fig. 1. WASp domain structure, interacting proteins, and activation.
Cytosolic WASp exists in an auto-inhibited conformation, with the
VCA domain tethered to the GBD and basic domains. This inactive state
is stabilized by WIP binding to the EVH1 domain. WASp is activated
by a variety of signals, including GTP-Cdc42, PIP2, and Y291
phosphorylation by SH3 kinases recruited by the polyproline domain.
Toca1 aids WASp activation by displacing WIP, binds GTP-Cdc42, and
is required for PIP2 activation of WASp. Activation is restricted to the
cell cortex where PIP2 and GTP-Cdc42 are present. Upon activation,
the VCA domain is free to bind to and activate Arp2/3. Active Arp2/3
then attaches to an existing actin filament, where Arp2 and Arp3 form
the template for a new actin filament branched at a 70° angle from the
parent filament.
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penia is quite different from both WAS and XLT and is the
result of a mutation within the GBD that disrupts the auto-
inhibited conformation of WASp, generating a constitutively
active protein. Four distinct mutations have been described
that cause XLN (L270P, S272P, I294T, and I276S), although
others in the same region would be expected to produce a
similar functional effect (22, 47–49).
The clinical presentation of the mildest form of disease,
XLT, may be restricted to microthrombocytopenia or may
present as a slightly more severe form with mild transient
eczema and occasional mild infections. Classical WAS pre-
sents as microthrombocytopenia with persistent eczema and
recurrent infections, which vary in severity and frequency in
different patients and may be frequently complicated by
autoimmunity and in some cases lymphoid malignancy.
XLN presents as neutropenia with recurrent bacterial infec-
tions and is discussed in more detail later.
Immune cell defects in WAS
The complex nature of WAS stems from the multiple func-
tional defects that occur in nearly all immune cells and
almost every step of the immune response, although to
varying extents. Here we discuss these defects by cell type
and immune compartment to present an overview of our
current understanding of how these defects combine to pro-
duce the multi-lineage disease phenotype, with immunode-
ficiency, autoimmunity and susceptibility to malignancy.
Hematopoiesis and homeostasis
WASp is expressed from the very earliest stages of the
hematopoietic system in the developing embryo (50).
Apparent non-random X-chromosome inactivation in WAS
carrier female patients points to a vital role in hematopoietic
cell homeostasis and survival (51). During development, the
hematopoietic system relocates from the fetal liver to the
bone marrow. Fetal liver hematopoietic cells in carrier
female mice have random X-chromosome inactivation, but
bone marrow cells have non-random inactivation of the
defective WAS X-chromosome. Therefore, WASp positive
cells have a selective homing advantage (52). However,
WAS patients and mouse models show normal bone marrow
cell numbers and proliferation, suggesting partial redun-
dancy between WASp and other WASp family members in
the developing hematopoietic system. While WASp defi-
ciency has only a small impact on hematopoiesis, the num-
bers of certain subsets of peripheral immune cells, especially
T cells, show an accelerated decline through childhood (53,
54). In experimental systems (and recently in clinical gene
therapy studies), a clear selective advantage for survival of
mature hematopoietic cells encompassing CD4+ and CD8+ T
cells, regulator T cells (Tregs), natural killer (NK) cells,
circulating B cells, splenic B cells, splenic macrophages, NK
cells, and platelets has been demonstrated (55, 56). This
may contribute to the observed high number of different
somatic revertants found in WAS patients, although other
undetermined molecular mechanisms are also likely to be
important. Somatic reversions are generally found in the
mature T-cell and NK-cell compartments (23), and although
some functional recovery would be expected, it has been
difficult to identify consistent clinical benefit, perhaps high-
lighting the multi-lineage nature of the disease (57). It may
also depend on the diversity of functional T cells generated
by reversion and the stage of differentiation and develop-
ment at which the cells accumulate.
Platelets
Microthrombocytopenia is consistently present in WAS and
XLT. The resulting tendency for bleeding is a significant
cause of morbidity and mortality (58). WASp expression in
platelets is extremely low, even when other cell types have
residual WASp expression, possibly because once produced,
anucleate platelets have a limited capacity to synthesize pro-
tein (59). Where mutant WASp expression has been demon-
strable in platelets, there was correlation with a milder level
of microthrombocytopenia (60). Despite the invariable
microthrombocytopenia in WAS and XLT, our understand-
ing of the role of WASp in platelet biogenesis and function
is rather limited. Platelet biogenesis begins in the bone mar-
row, where megakaryocytes extend pro-platelet elongations
that are then released into the vasculature where they con-
tinue to mature and finally release platelets (61). WASp null
megakaryocytes have abnormal actin cytoskeletal architec-
ture, but despite a premature release of pro-platelets in vivo
(62), in vitro studies show WAS megakaryocytes generate
pro-platelets and platelets of normal size and numbers (63).
Thrombocytopenia in WAS actually appears primarily to be
due to increased platelet clearance, even in the absence of
concurrent autoimmunity. WASp null platelets are cleared
more rapidly than normal platelets when transferred to
wildtype mice, due to increased phagocytosis by splenic,
bone marrow, and liver macrophages, and compounded by
autoimmune anti-platelet antibodies (64–66). Consistent
with the idea that increased clearance is a major factor in
microthrombocytopenia, splenectomy has been shown to
© 2013 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
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give a consistent and marked improvement in both platelet
number and size, although thrombocytopenic relapse may
occur in the presence of anti-platelet antibodies (67–70).
WAS platelets are small and misshapen in non-splenectom-
ized patients but show a remarkably normal size, shape, and
function in splenectomized patients (reviewed in 21).
Innate immunity: myeloid cells
Myeloid phagocytic cells of the innate immune system form
the frontline of defense against invading pathogens. These
cells detect and migrate toward pathogens, release signaling
molecules, produce toxic metabolites, phagocytose, and
destroy their targets. Studies of WAS patient-derived cells
and animal models demonstrate how an inability to reorga-
nize the actin cytoskeleton impacts on all of these processes.
WAS phagocytic cells have a poor chemotactic response
toward inflammatory chemoattractants such as bacterially
derived fMLP, and the chemokines c5a, MCP-1, and CSF-1
(53, 71–73). These migration defects are most apparent
under conditions of shear flow or when studied in vivo in
WAS knockout mice or WAS knockdown zebrafish embryos
(73–75). The failure to polarize the cytoskeleton and direct
integrin clustering has knock on effects, such as reduced
levels of neutrophil oxidative burst and degranulation (75).
Mechanistically, the lack of WASp prevents cytoskeletal
rearrangements, including podosome formation (75–78),
that are required to guide adapter proteins such as vinculin
and talin to physically induce integrin clustering necessary
for adhesion to surrounding tissues (79, 80). WASp-deficient
cells are unable to maintain directional protrusions during
migration (81) and lose cellular polarity between the leading
pseudopod and trailing uropod due to failure to direct inte-
grin CD11b to the uropod where it stabilizes microtubules
(82). Despite these migration defects, some cells do success-
fully migrate to the target site but show defective phagocyto-
sis of pathogens (83, 84) and apoptotic cells (85, 86). These
phagocytic defects result from compromised actin-driven
phagocytic cup formation (79), which normally relies on
phospholipase D2 and Grb2 binding to WASp (87).
Innate immunity: lymphoid NK and iNKT cells
NK cells are lymphoid innate cells that migrate toward sites
of infection and inflammation, where they detect virally
infected cells, parasites, and malignant cells, and kill them
via the release of cytotoxic proteins (88). The activation of
NK cells is severely compromised in WAS, as it relies on the
formation of an immune synapse, which is dependent on
WASp mediated actin polymerization (89). Surprisingly, NK
cell function and immune synapse formation can be restored
in the presence of interleukin-2 (IL-2) (90) through activa-
tion of WAVE-2, even in the absence of WASp (91).
Invariant NKT (iNKT) cells blur the boundary between
innate and adaptive immunity, expressing receptors typical
of both NK cells and T cells. They recognize lipid antigens
presented via the non-classical major histocompatibility
complex (MHC) class I molecule CD1d and possess an
invariant T-cell receptor a chain (92). iNKT cells act early in
the immune response, release a wide variety of cytokines,
including IL-4 and interferon-c (IFNc), and appear to have
important functions in antitumor activity and autoimmunity
(92, 93). The low numbers of iNKT cells together with
defective function of NK cells (94, 95), may well provide
an important contribution to disease phenotype.
Antigen presentation: dendritic cells
The interaction between the professional antigen-presenting
cells of the innate immune system and lymphocytes of the
adaptive immune system represents a major focus of research
in WAS. These studies highlight the variety of defects that a
loss of actin cytoskeletal rearrangement can cause.
Migration of dendritic cells (DCs) toward sites of inflam-
mation is impaired in vivo due to failure to polarize. Lack of
podosome formation and poor integrin assembly reduce the
adhesion to intercellular adhesion molecule-1 (ICAM-1)
needed for migration over the endothelium (80, 96–100).
DC uptake of soluble antigen is normal in WAS, but phago-
cytosis and presentation of particulate antigens is impaired
(101). The migratory defects in WAS DCs may also contrib-
ute to failure of DCs to correctly localize in secondary
lymphoid tissues, with dyslocalization seen in both lymph
nodes and spleen (98, 99). Poor DC migration after antigen
uptake may lead to maturation of DCs before they reach
lymph nodes, with ectopic cytokine and chemokine release
likely to recruit other immune cells that may contribute to
inflammatory processes such as eczema.
The reduced numbers of DCs that do arrive at the lymph
nodes have a depleted ability to form an immune synapse
and present antigen. This defect is very well characterized
on the lymphocyte side (see below), but is also due to
specific defects in the DC. Activation of normal (expressing
wildtype WASp) T cells and NK cells by WAS DCs is
impaired both in vitro and in vivo (100, 102, 103). This is a
result of reduced IL-12 release from the DC and also from
poor immune synapse formation (104). In these experi-
© 2013 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
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ments, although T cells had normal WASp activity, these T
cells failed to efficiently polarize T-cell receptors (TCRs),
LFA-1, talin, and F-actin, resulting in diminished TCR sig-
naling and demonstrating that DC-specific defects signifi-
cantly contribute to WAS. For example, a DC-specific defect
of type I IFN production could explain compromised antivi-
ral immunity (105).
Adaptive immunity: T cells
Thymic T-cell development is surprisingly intact in WAS,
although detectable abnormalities do exist (106, 107). Mature
WAS T cells exhibit morphological changes, with fewer mi-
crovilli, but the significance and impact of these changes are
not clear (108, 109). WAS T cells have a marked migration
deficiency, with poor adhesion and failure to respond to the
chemokines CCL19 and CCL21(73). A major defect in WAS T
cells is their failure to proliferate in response to immune acti-
vation following TCR ligation and in the context of an
immune synapse (IS) (53, 84, 106, 110, 111). Abnormal IS
formation results from actin polymerization defects, failure to
mobilize lipid rafts, and poor assembly of the signaling part-
ners that normally rely on WASp for localization to the TCR
(112, 113). The IS is a highly dynamic structure that cycles
through stable symmetrical and unstable asymmetric forms,
with WASp required for stable IS reformation after protein
kinase Ch (PKCh)-triggered IS disruption (114). Therefore,
while the initial formation of the IS may be reasonably normal
in WAS, it is inherently unstable and cannot maintain symme-
try. In the absence of WASp, the IS can form normally if there
is strong costimulation and antigen concentration is high
(115). This observation suggests WASp function in IS forma-
tion may be redundant given sufficient costimulation. How-
ever, signaling downstream of TCR ligation is consistently
reduced due to failure to translocate the transcription factor
nuclear factor of activated T cells (NFAT) to the nucleus. This
translocation requires the EVH1 domain of WASp and is inde-
pendent of WASp Arp2/3 activation (116, 117). These signal-
ing failures mean WAS CD4+ T cells fail to secrete normal
amounts of the T-helper 1 (Th1) cytokines IFN-c and tumor
necrosis factor-a (TNF-a), but Th2 cytokine (IL-4, IL-5, and
IL-10) production is near normal (116).
An unanticipated role for WASp in the nucleus has been
reported that may provide an explanation for the Th1-Th2
imbalance in WAS (118). In this study, WASp was shown
to localize specifically to the Th1 master gene TBX21 and is
necessary for TBX21 transcription through an epigenetic
mechanism involving histone methyltransferase recruitment.
Interestingly, a WASp mutant found in the mildest form of
XLT retained TBX21 localization and permitted normal TBX21
transcription.
Adaptive immunity: B cells
Despite clear humoral immune defects, low immunoglobulin
M (IgM) levels, elevated IgA and IgE, and increased inci-
dence of B-cell malignancy (119), B-cell function in WAS
has received much less attention. Initial reports showed little
impact of WASp deficiency in B cells (84, 106, 120), with
the exception of a conflicting report of failure of Epstein–
Barr virus (EBV) immortalized WAS B cells to proliferate
(121). B-cell defects were limited to decreased antibody
responses to polysaccharides (54, 119) and fewer microvilli
(84). However, more detailed analysis of B cells in WAS
revealed that these cells did have marked abnormalities,
including defective polarization, spreading, aggregation, and
migration toward CXCL13 in vitro, few microvilli, and
delayed humoral immune response in mice (122, 123). This
was supported by the finding of poor adhesion, abnormal
actin cytoskeletal architecture, defective IS formation, and
augmented apoptosis in human pre-B cells (55, 124). Condi-
tional depletion of WASp in B cells also results in hyperpro-
liferation (125, 126). Splenic architecture is abnormal in
WAS mice and humans, but marginal zone B-cell numbers
are characteristically low, perhaps due to failure to migrate
toward sphingosine-1-phosphate and CXCL13 (36, 55, 56,
123, 127, 128). B-cell defects are most pronounced in
mature B cells, where WASp expression is normally highest
(55), with developing B cells able to partially compensate
possibly through N-WASp (129). Autoantibody production
is a common feature in WAS (119, 130, 131), although the
mechanisms behind this are poorly understood.
Autoimmunity and malignancy
Autoimmunity is common in classical WAS, eventually
affecting the majority of patients if untreated by hematopoi-
etic stem cell transplantation (HSCT) or more recently gene
therapy (132). Management of autoimmune manifestations
is becoming increasingly important as the treatment of
immunodeficiency and thrombocytopenia improves (119,
130, 133, 134). Antibody-mediated cytopenias are the most
common autoimmune presentation, followed by vasculitis,
arthritis, colitis, and nephritis (22). Autoimmunity can
occur or persist even after successful HSCT and may corre-
late with the level of chimerism achieved (133, 134).
Recent studies have begun to unravel the causes of
© 2013 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
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autoimmunity in WAS, but our knowledge in this area is
limited to a few key studies and will likely be an area of
active research for some time. Autoimmunity is thought to
result from a breakdown of tolerance to self-antigens, giving
rise to autoreactive T and B cells. Tolerance is maintained by
Tregs (135) and also the recently described regulatory B
cells (Bregs) (136, 137). There was very little mechanistic
understanding of autoimmunity in WAS until four reports
published in 2007 demonstrated a variety of functional
defects in Tregs, even though defects of apoptotic cell clear-
ance had been described (85, 86, 138–141). WAS Tregs fail
to proliferate after TCR activation, show lower levels of acti-
vation markers such as CD25, produce less immunosuppres-
sive IL-10, lack tissue homing markers (potentially explain-
ing the very low numbers of Tregs at sites of inflammation
and lymph nodes), and have reduced suppressive activity
both in vitro and in vivo. The loss of Treg function is partly
attributable to the low levels of CD25 (part of the IL-2
receptor) and addition of exogenous IL-2 can partially
restore Treg function in vitro. This is likely compounded by
the lack of IL-2 production from WAS effector T cells,
although in vivo the presence of wildtype effector T cells
with normal IL-2 secretion is unable to prevent autoimmu-
nity (141). The loss of Treg activity also impacts on B-cell
tolerance, as WAS Tregs are inefficient in preventing B-cell
proliferation, and show reduced killing of B cells, poor
polarization, and little secretion of the apoptosis inducing
protein granzyme B (142). Another contributing factor is a
reduction in restimulation-induced cell death (RICD) in
WAS. RICD is a process that acts to remove T cells respon-
sive to persistently expressed antigens such as autoantigens.
In WAS, RICD-induced apoptosis is reduced in CD4+ T cells,
possibly because of low production of vesicular FasL (143).
WASp deficiency also plays a B-cell-intrinsic role in the
production of autoantibodies. Removal of self-reactive B cells
is largely dependent on the strength of the BCR signal (144,
145). Mouse WAS B cells are hyper-responsive to B-cell
receptor and Toll-like receptor signaling, leading to a loss of
immune tolerance (125). The kinetics of B-cell receptor
internalization after engagement are much slower in WAS B
cells, possibly due to defective cytoskeletal rearrangement
(125). However, while WAS mice show elevated levels of
autoantibodies, they show little sign of autoimmunity, possi-
bly due to the wider WAS immunodeficiency and particu-
larly the lack of T-cell help (24, 125). However, when
WASp deficiency is restricted to B cells by conditional knock-
out of WAS in the B-cell lineage, mice develop severe
autoimmunity, spontaneous germinal center formation,
hyper-proliferation of germinal center B cells and plasma cells
in vivo, and excessive differentiation of class switched plasma-
blasts in vitro (125, 126). The role of IL-10 producing Breg
cells has not been properly explored but may well also be
important for control of autoimmune processes (136, 137).
WAS patients have an increased risk of malignancy,
particularly B-cell lymphoma. Inefficient killing of B-cell
lymphoma targets by WAS cytotoxic T lymphocytes, owing
to poor polarization and delivery of cytotoxic granules to
the T-cell/target cell interface and also lower cytokine (IL-2,
IFN-c, and TNF-a) production may contribute, together
with functional deficiency of NK and NKT cells (146).
Malignancy risk in WAS is another area that needs further
investigation and will pose a greater problem as long-term
disease management improves. Overall, the mechanisms
behind susceptibility to malignancy are incompletely under-
stood, in terms of intrinsic cellular contribution as well as
systemic immunodeficiency.
Other actin-related immunodeficiencies
WAS is the first in a growing list of genes whose disruption
result in immunodeficiencies that are due to cytoskeletal
abnormalities. These genes show a range of activities and
interactions with the cytoskeleton, including a mutation in
actin itself, actin bundling, actin severing, inhibition, and
promotion of actin polymerization, signal transduction, and
transcription (Table 1).
X-linked neutropenia
XLN is characterized by severe neutropenia and monocytope-
nia, a marked reduction in NK cells, skewed CD4+/CD8+ T-
cell ratios, and recurrent bacterial infections (49). Surpris-
ingly, the gene identified as causing XLN is WAS, with four
mutations described, L270P, S272P, I276S, and I294T, clus-
tered together in the GBD of WASp (22, 47–49). These
mutations disrupt the auto-inhibited conformation of WASp,
generating a constitutively active protein. Consequent activa-
tion of the Arp2/3 complex triggers uncontrolled actin poly-
merization and an increase in cellular F-actin content.
At the cellular level, defective cytoskeletal dynamics in
XLN result in abnormal phagocytosis, migration, and podo-
some dynamics (47). Although oxidative burst in neutroph-
ils is normal in response to PMA, receptor-mediated
oxidative burst in response to E. coli or fMLP is reduced,
suggestive of an inability to effectively assemble signaling
complexes at the cell membrane (47). In addition to cytope-
nias and myeloid defects in XLN, T-cell proliferation is
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Table 1. Actin cytoskeletal immunodeficiency: phenotypes and candidate genes
Protein (gene)
Expression profile
and function
Disease or
mouse model Phenotype
WASp – Wiskott-Aldrich
Syndrome Protein (WAS)
Hematopoietic.
Arp2/3 activator.
Branched F-actin
network assembly.
Transcription factor
activation. Epigenetic
chromatin remodeling
Wiskott-Aldrich
Syndrome (WAS)
X-Linked
Thrombocytopenia (XLT)
X-Linked
Neutropenia (XLN)
Severe combined immunodeficiency. Autoimmunity,
malignancy. All immune lineages affected.
Multiple cytoskeletal cellular defects.
Thrombocytopenia, mild immunodeficiency.
Neutropenia, excessive F-actin production.
Cell division defects
WIP – Wiskott-Aldrich
Syndrome Protein
Interacting Protein (WIPF1)
Hematopoietic.
WASp chaperone.
Prevents WASp
proteolysis, aids WASp
recruitment, and
regulates activity.
Novel human
immunodeficiency
Identical to WAS
Dock8 – Dedicator of
cytokinesis 8 (DOCK8)
All tissues, strong
hematopoietic expression.
Atypical guanine
exchange factor.
Signaling from
surface receptors
to cytoskeletal
regulators,
signal transduction
Dock8 deficiency.
Autosomal recessive
hyper-IgE
syndrome (AR-HIES)
Severe combined immunodeficiency. Autoimmunity,
malignancy.
All immune cell lineages affected? Multiple
cytoskeletal cellular defects.
Signal transduction impaired in B-cell proliferation
(and other cell types?)
Rac2 Ras-Related C3
Botulinum Toxin
Substrate 2 (RAC2)
Hematopoietic.
Rho GTPase, signal
transduction, cytoskeletal
remodeling
Neutrophil
immunodeficiency
syndrome
Neutrophil chemotaxis, actin polymerization,
oxidative burst. Mouse: Low thymic output, HSC
apoptosis, Poor T-cell activation and proliferation,
B-cell activation, migration
RhoH ras homolog
family member H (RHOH)
Hematopoietic.
Atypical Rho GTPase,
signal transduction,
cytoskeletal remodeling
Epidermodysplasia
verruciformis
Increased memory T cells, restricted TCR usage.
Persistent EV-HPV infection.
Mouse: Poor HSC proliferation, dysregulated
F-actin production. T-cell deficiency, T-cell
development, TCR signaling, migration
Coronin 1A coronin,
actin-binding protein,
1A (CORO1A)
Hematopoietic.
Arp2/3 inhibitor
Severe combined
immunodeficiency
with CORO1A mutation
Naive T-cell deficiency, defective egress from the
thymus, reduced TCR repertoire, lack
of iNKT cells.
Mouse: increased F-actin in T cells, increased
T-cell apoptosis, TCR signaling defect
b-Actin (ACTB) All tissues.
Main Actin protein
A unique neutrophil
dysfunction
Poor neutrophil chemotaxis, oxidative burst and
actin remodeling. Thrombocytopenia
Leukocyte
specific protein 1 (LSP1)
Hematopoietic.
Actin bundling
Neutrophil actin dysfunction
syndrome (NAD47/89)
LSP1 overexpression impedes neutrophil and
macrophage migration and phagocytosis
L-Plastin (LCP1) Hematopoietic.
Actin bundling
Mouse model, cell lines Multiple hematopoietic lineages affected. Oxidative
burst, signaling, motility, adhesion defects reported
RhoG ras homolog
family member G (RHOG)
Hematopoietic.
Rho GTPase,
signal transduction,
cytoskeletal remodeling
Mouse model Increased IgG1 and IgG2B, small increase B and
T-cell proliferation after activation. Macrophage
phagocytosis defective, oxidative burst defect, TCR
capping and internalization defect
AIP1/WDR1 – Actin-Interacting
Protein 1/WD repeat
domain 1 (WDR1)
All tissues.
Enhances actin
depolymerization in
cooperation with cofilin
Mouse model, cell lines Autoinflammatory disease. Excessive neutrophil
numbers at inflammation sites. Excess F-actin,
defective migration
MKL1/MAL/MRTF-A –
Megakaryoblastic Leukemia
1 (MKL1)
All tissues.
Senses the G-actin pool,
transcriptional
co-activator of
SRF, control many
actin-related genes
Mouse models Megakaryocyte development perturbed.
Thrombocytopenia
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reduced in response to CD3 stimulation, and spontaneous
apoptosis of bone marrow-derived progenitor cells and
Fas-mediated apoptosis of lymphocytes are increased (47).
B-cell morphology is abnormal, B-cell rolling on L-selectin
is impaired (147), and B and T-cell spreading is reduced
(148).
In vitro studies using forced overexpression of WASpI294T
showed that the reduced proliferation and cytopenias in
XLN are caused by ectopic F-actin impeding mitosis and
cytokinesis, leading to apoptosis and genomic instability.
These cell division defects are a result of altered cell
mechanics. Constitutively active WASp is active throughout
the cytoplasm, so branched F-actin networks, normally
restricted to the cortex, form throughout the cell. The
resulting network of cytoplasmic F-actin increases cellular
viscosity and elasticity (7, 149). These changes in cell
mechanics directly impede cell division by resisting the
movement of mitotic chromosomes and by slowing the clo-
sure of the actomyosin ring during cytokinesis (149, 150).
The cell responds to these mitotic abnormalities through the
activity of a cell cycle regulating kinase, Aurora B, and also
compensates for increased viscosity by strengthening the
mitotic spindle. Despite these compensatory mechanisms,
division defects frequently occur in XLN cells. In addition to
the genomic instability observed in vitro, evolution to myelo-
dysplasia or AML with acquisition of CSF3R mutations and
monosomy 7 has been reported in XLN patients (47, 151),
and aneuploidy is also evident in a mouse model of disease
(148).
WIP deficiency
Female carriers of WAS gene mutations can develop clinical
manifestations of disease if X-inactivation is sufficiently
skewed. A female patient with the classical symptoms of
WAS, including eczema, thrombocytopenia, recurrent infec-
tions, defective T-cell proliferation and chemotaxis, and
impaired NK cell function was found to have normal WAS
gene sequence and mRNA levels but a complete absence of
WASp expression (152). Because WIP stabilizes WASp (32–
34), WIP expression was assessed. WIP protein was reduced
by approximately 50% in both parents, and completely
absent in the patient. WIPF1 gene sequencing revealed a
homozygous nonsense mutation in the patient, resulting in
a truncated 435 amino acid WIP protein lacking the WASp
binding domain (aa 451–485) (153). This novel route to
WASp deficiency should be considered in patients that pres-
ent with WAS phenotype but have a normal WAS gene.
DOCK8
Dedicator of cytokinesis 8 (DOCK8) was isolated in a yeast
two-hybrid screen for proteins interacting with Cdc42, and
DOCK8 also binds to Rac1, RhoJ, and RhoQ (154). DOCK8
mRNA is present throughout most tissues, with strong pro-
tein expression in hematopoietic cells and peripheral blood
mononuclear cells (PBMCs). DOCK8 localizes to cell edges
during lamellipodia formation (154), and is part of the
Dock180-related family of atypical guanine exchange factors
(GEFs). GEFs in general activate Rho GTPases by facilitating
the switch from a GDP-bound to GTP-bound state. The Rho
GTPases, in turn, integrate extracellular signals and transduce
these to effector molecules (i.e. GTP-Cdc42 activates WASp)
to produce an appropriate cytoskeletal response (155).
In 2009, DOCK8 mutations were independently described
as the cause of severe immune deficiency in both humans and
mice (156–158). The syndrome was originally described as
an autosomal recessive form of hyper IgE syndrome (AR-
HIES), due to several shared features, such as elevated IgE,
respiratory infections, and eosinophilia. However, using
high-resolution comparative genomic hybridization, Zhang
et al. (157) discovered homozygous or compound heterozy-
gous deletions and point mutations in DOCK8 in 11 patients
who had previously been diagnosed with AR-HIES or
unknown combined immunodeficiencies. It has since been
shown that DOCK8 mutations account for the majority of
cases of AR-HIES with over 60 patients now reported in
literature (157–167).
Clinical characteristics of DOCK8 deficiency include severe
food or environmental allergies, otitis media, pneumonia,
or bronchitis, eczema, eosinophilia, IgE dysregulation, and
severe cutaneous viral infections, with the most common
culprits being human papilloma virus (HPV), molluscum
contagiosum virus, herpes simplex virus, and varicella-zoster
virus (157, 158, 161). Systemic viral infections are rarely
detected, suggesting defects in antiviral immunity locally
within the skin (158, 168). Susceptibility to viral infections
is seen in other PIDs such as WAS and ‘leaky’ SCID
(169–171). As in WAS, the increased susceptibility to viral
infections could be the result of a combination of factors
including defective skin barrier, reduced numbers of T cells,
impaired T-cell proliferation and antiviral cytokine produc-
tion, and abnormal migration into infected tissues (172).
Pneumonias in DOCK8 patients are caused by a wide spec-
trum of Gram-positive and Gram-negative bacteria and
fungi. Gastrointestinal tract infections, including Giardia and
Salmonella, have also been reported (157, 158).
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DOCK8 is a key regulator of actin cytoskeletal dynamics,
and as such DOCK8 deficiency elicits a broad range of
immune cell defects. Despite the distinct clinical presenta-
tion of DOCK8 compared to WAS, many of the cellular
defects are shared between these two syndromes. T-cell
defects common to DOCK8 deficiency and WAS include
decreased proliferation in vitro (157, 158) and fewer
memory T cells in vivo (173, 174). Both syndromes show
decreased antiviral cytokine (IFN-c and TNF-a) production
by CD8+ T cells, although in DOCK8 deficiency granule
release appears normal (157). The Th1-Th2 imbalance in
WAS might also be a feature of DOCK8 deficiency, as some
patients have elevated levels of IL-6 and IL-10 (162).
DOCK8 deficiency also shows T-cell defects not described in
WAS. Low numbers of Th17 cells in DOCK8 deficiency
(175, 176) may contribute to poor antifungal immunity.
There is also evidence of impaired T-cell production or
efflux from the thymus (162). It is still not clear to what
extent defective TCR signaling, cytokine production, and
homeostatic proliferation of peripheral cells contribute to
the overall T-cell defects. The defective functioning of CD8+
T cells, which normally assist in tumor surveillance, may
contribute to the higher rate of malignancies in DOCK8
patients. Around 20% of patients develop at least one type
of cancer, and the most common malignancies are squa-
mous cell carcinoma and lymphoma (168).
In the B-cell compartment, marginal zone B cells are lack-
ing in both WAS and DOCK8 deficiency, and B cells in both
syndromes have poor IS formation due to a failure to con-
centrate LFA-1 and ICAM-1 in the pSMAC (peripheral supra-
molecular activation cluster) (55, 156, 177). Competitive
hematopoietic chimeras have shown that DOCK8 mutant B
cells contributed normally to circulating B cells but poorly to
the germinal center (GC) subset, in particular during response
maturation, suggesting that the mutation causes an intrinsic
B-cell defect affecting their ability to differentiate into or sus-
tain a GC fate. DOCK8 mutant B cells also undergo normal
immunoglobulin gene hypermutation; however, diminished
survival and selection resulted in severely reduced numbers
of high-affinity IgG+ B cells (156). The high frequency of
recurrent infections in DOCK8 patients implies defects in
humoral immunity. However, serum IgA levels, important
for mucosal immunity, are reduced only in a minority of
patients while most show normal or increased titers (157,
158), similar to WAS. It is not clear how DOCK8 patients
exhibit hypo-IgM and hyper-IgE. However, DOCK8 was
recently shown to transduce signals between TLR9 and
STAT3 via MyD88, a novel signaling pathway for
TLR9-driven B-cell proliferation and immunoglobulin pro-
duction (177).
There are relatively few studies of other cell type-specific
defects in DOCK8 deficiency. DOCK8 DCs show similar
defects to those found in WAS. That is, defective cytoskeletal
reorganization with decreased migration to lymph nodes,
slow velocity through dermal tissues and poor T-cell prim-
ing, although antigen uptake and presentation is normal
(178). NK cell numbers are normal in DOCK8 deficiency,
but unlike WAS, DOCK8 NK cells show normal F-actin
levels. However, similar to WAS, DOCK8 NK cells are
unable to polarize F-actin toward the lytic synapse, with
impaired clustering of CD18, and lack of polarization of
perforin and the microtubule organizing center (179). In
WAS, cytolytic activity of NK cells can be restored by IL-2
as the cytokine can bypass WASp to use the homologous
effector WAVE2 (91). This is not the case for DOCK8 NK
cells; IL-2 stimulation had no effect on NK cell functions in
the absence of this upstream activator (179).
The disease pathology of DOCK8 deficiency is likely to be
the result of a combination of cellular defects including the
inability of B cells to generate high-affinity antibodies and
sustain GCs, the absence of T-cell memory, defects in DC
migration, capacity to prime T cells, and reduced NK cell
cytotoxicity. In mice, DOCK8 mutations replicate many of
the cellular defects described in human disease, but mice
show no obvious clinical phenotype, another similarity to
WAS (84, 106). Some of the symptoms described, such as
rash, elevated IgE, and susceptibility to autoimmunity, are
very similar to those described in WAS (22). As an effector
of the Rho GTPase Cdc42, WASp presumably acts down-
stream of DOCK8, and the similar clinical manifestations
may reflect the overlapping signaling pathways. While
WASp function may also be diminished in DOCK8 patients,
this cannot explain the complete phenotype of DOCK8 defi-
ciency, and other downstream DOCK8 effectors such as
N-WASp may also be involved. Interestingly, mice generated
to delete WAS and N-WAS in lymphocytes show an exagger-
ated cellular phenotype (107, 129).
Rac2, RhoH, and the Rho GTPase signaling pathway
The 20 mammalian Rho GTPases constitute a highly con-
served family of signaling proteins that activate downstream
targets including actin nucleators, protein kinases, and
phospholipases, to regulate cytoskeletal dynamics, transcrip-
tion, and proliferation (180, 181). In addition to immuno-
deficiency due to defects in upstream regulators (DOCK8),
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downstream effectors (WASp) of Rho GTPase signaling,
immunodeficiency can also result from mutations in the
Rho GTPases themselves.
The Rho GTPase Rac2 is restricted to hematopoietic cells
and is abundantly expressed in neutrophils, constituting
96% of the total Rac in these cells (182). RAC2 KO mice
revealed an essential role for Rac2 in neutrophil chemotaxis,
L-selectin capture and rolling, F-actin generation, chemoattr-
actant-driven activation of p38 and p42/44 MAPKs, and
oxidative burst (183). In humans, RAC2 mutation is the
cause of neutrophil immunodeficiency syndrome (182,
184). This remains an extremely rare disorder, with a third
case described in 2011 (185). All three cases share an iden-
tical D57N mutation, within the DX2G motif conserved in
all GTPases, resulting in a dominant negative-acting protein.
Analysis of patient samples showed poor neutrophil chemo-
taxis, lack of actin polarization, diminished granule secre-
tion, and no oxidative burst in response to fMLP, although
oxidative burst is present following direct activation of PKC
(182, 184, 185). The rarity of RAC2 mutations has limited
its study in a human setting, and only one further cellular
defect has been described in human Rac2 disease: impaired
thymic T-cell production, possibly related to defective T-cell
integrin function (185).
Studies using mouse models of Rac2 deficiency, with
dominant negative D57N Rac2 or RAC2 KO, not only reca-
pitulate the neutrophil defects (186–188) but have also
revealed a far wider impact, encompassing almost all aspects
of immune function (181). HSCs show increased apoptosis
and loss of retention in the bone marrow (186, 189, 190).
T lymphocytes show reduced activation following TCR acti-
vation, defective cytoskeletal reorganization, and lack of Th1
signaling and IFN-c production (191, 192). B-cell develop-
ment, cytoskeletal reorganization, activation through BCR
signaling, and migration to chemokines are all defective
(193–195). Macrophages display phagocytic and oxidative
burst deficiency similar to neutrophils (196), and the CD8+
subpopulation of DCs also lacks oxidative burst capacity
(197), while eosinophils have impaired migration and actin
polymerization (198).
RhoH is an atypical Rho Family GTPase that lacks GTPase
activity and acts by inhibiting other GTPases. RhoH expres-
sion is restricted to hematopoietic cells, and knockout mice
develop normally but display a range of immune cell dys-
functions. HSC proliferation and migration are perturbed
due to excessive Rac1 activity, resulting in enhanced F-actin
production, as the normal Rac1 inhibitory activity of RhoH
is absent (199, 200). T-cell development, TCR signaling and
migration are all disturbed, resulting in T-cell deficiency
(201–203). Recently a loss of function mutation in RhoH
was identified as a novel cause of a rare genetic disorder,
epidermodysplasia verruciformis, which normally results
from mutation of the eponymous gene (204). The two
patients described had recurrent infectious diseases, most
notably persistent EV-HPV infection. T cells were skewed
toward effector memory cells with restricted TCR usage and
poor TCR signaling. T-cell homing appears to be deficient
due to lack of b7 integrin expression, which may explain
the persistent EV-HPV infections.
Coronin 1A
Coronins are actin regulatory proteins conserved in all
eukaryotes. In mammals, seven members are expressed and
can be classified into three types: I, II, and III. Type I coro-
nins include Coronin 1A, B, and C. Although Coronin B and
C are ubiquitous, Coronin 1A is restricted to hematopoietic
cells. Type I Coronins regulate actin filament branching by
restricting nucleation of branched actin filaments at the lead-
ing edge, either by inhibiting the attachment of the Arp2/3
complex or directly facilitating debranching (205). Studies
in mice revealed a role for Coronin 1A in actin dynamics in
T cells, T-cell homeostasis and trafficking, with a calcium
signaling defect downstream of TCR and B-cell receptor acti-
vation, resulting in reduced proliferation and IL-2 produc-
tion (206–209). In humans, Coronin 1A mutations have
been reported to cause severe combined immunodeficiency,
with severe peripheral T-cell deficiency, especially in naive
T cells, near complete absence of iNKT cells, and suscepti-
bility to EBV-induced lymphoproliferation (210–212). Inter-
estingly, in a mouse model of systemic lupus erythematosus
(SLE), loss of Coronin 1A activity in T cells completely
suppressed the autoimmunity normally present in SLE
(209).
b-Actin
As the main component of the actin cytoskeleton, it is sur-
prising that a non-lethal mutation in the b-Actin gene
(ACTB) has been reported that results in immunodeficiency
(213). The patient presented with recurrent infections,
thrombocytopenia, intellectual impairment, and short stat-
ure. A heterozygous mutation in ACTB resulting in an
E346K substitution was identified, in a region of the protein
that is reported to bind a number of cytoskeletal regulators.
The major immune defect was poor neutrophil chemotaxis
and oxidative burst and failure to polarize the cytoskeleton
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in response to fMLP. No other immune dysfunction was
reported. Further studies of this mutation have not yet been
performed.
Leukocyte-specific protein 1
Leukocyte-specific protein 1 is an actin-binding phosphopro-
tein mainly expressed in neutrophils, macrophages, B and T
lymphocytes, and endothelial cells (214). It binds actin
through caldesmon and villin homologous actin-binding
domains, reorganizes actin filaments into bundles, and local-
izes to F-actin in lamellipodia, filopodia, and membrane ruf-
fles (215–218). A mouse knockout model for LSP1
demonstrated increased migration of neutrophils and macro-
phages toward inflammatory sites, and enhanced chemotaxis
toward fMLP and chemokines, indicative of a negative regula-
tory role of LSP1 in chemotaxis (219). LSP1 was identified as
a 47 kDa protein overexpressed in neutrophil actin dysfunc-
tion syndrome (NAD47/89), a disease characterized by recur-
rent bacterial infections and immotile neutrophils (220, 221).
Overexpressed LSP1 alters actin organization, generating F-
actin spikes at the cell surface, with impaired chemotaxis,
phagocytosis, and cell spreading. However, the genetic basis
of the patient described with neutrophil actin dysfunction
syndrome has not yet been characterized.
Candidate genes for actin immunodeficiencies
Seven genes have been identified as causing human actin-
related immunodeficiency: WAS, WIPF1, DOCK8, RAC2, RHOH,
CORO1A, and ACTB. Five of these are involved in Rho GTPase-
mediated cytoskeletal organization (WASp, WIP, DOCK8,
Rac2 and RhoH), Coronin 1A negatively regulates Arp2/3,
and b-Actin is the central component of the cytoskeleton.
Given that over 100 proteins are directly involved in actin
cytoskeletal regulation (5), there is a clear potential for the
identification of other actin-related immunodeficiencies.
Some examples are shown below.
RhoG
Mutations in all three key stages of Rho GTPase signaling have
been described in immunodeficiency: the effectors (WASp),
the GTPases (Rac2 and RhoH), and the upstream modulators
(the Rho/Rac GEF DOCK8), suggesting this pathway is partic-
ularly important in immune function. The majority of Rho
GTPase signaling molecules has a wide tissue distribution and
loss of activity has major consequences beyond immune cell
function. However, while RhoG is widely expressed and
functions in many tissues, it is most highly expressed in
lymphocytes (181). RhoG KO mice develop normally, have
normal numbers of B and T cells, increased IgG1 and IgG2b,
and a small increase in B and T-cell proliferation following
TCR or B-cell receptor activation (222). RhoG is also
important for oxidative burst and both FccR and complement
receptor 3-mediated phagocytosis and has recently been
shown to be essential in the internalization of the TCR and
bound MHC class II complex (223–225).
L-plastin
L-plastin is an actin-bundling protein whose expression is
restricted to hematopoietic cells (226, 227). Knockout of
L-plastin in mice revealed an essential role in neutrophil oxida-
tive burst and bacterial killing (228). There are now numerous
reports of a variety of murine and cell line immune defects due
to L-plastin deficiency. L-plastin plays important roles in both
myeloid and lymphoid lineages, in receptor signaling, adhe-
sion, and motility (reviewed in 229), and as such is a strong
candidate for human immunodeficiency.
AIP1
In mice, knockout of the Actin-interacting protein 1 gene
(AIP1) is embryonic lethal, but hypomorphic mutation
results in macrothrombocytopenia and autoinflammatory
disease characterized by excessive neutrophil recruitment to
inflammation sites (230). AIP1 is ubiquitously expressed
and promotes actin filament disassembly via cofilin (231).
The precise mechanism for AIP1 actin severing is not
known. AIP1 alone has little effect on actin dynamics, but in
the presence of cofilin, AIP1 may directly sever actin filaments
(232–234), and/or cap the barbed ends of filaments severed
by cofilin (233, 235). AIP1 activity is further enhanced by
interactions with coronin and the immunomodulatory cas-
pase-11 (236–238). Depletion of AIP1 in the Jurkat T-cell
line impairs migration through generation of multiple mem-
brane protrusions rather than the single lamellipodium
required for directed migration (239). AIP1 KO neutrophils
show increased levels of F-actin, but a loss of cortical
F-actin, cofilin mislocalization, and reduced migration
(230). Partial loss of AIP1 function may result in similar
immune dysregulation in humans.
MKL1
Megakaryoblastic leukemia myocardin-like 1 (MKL1/MAL/
MRTF-A) is an actin-binding co-factor that senses G-actin con-
centration and is a co-activator of the transcription factor serum
response factor (SRF) (240). Over 100 SRF target genes have
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actin cytoskeletal functions, of which 28 are directly dependent
on MKL1 activity (241, 242). Knockout ofMKL1 in mice results
in megakaryocyte maturation defects and thrombocytopenia,
and may therefore mimic some aspects of WAS (243–245).
Summary and conclusions
Immunodeficiencies due to actin cytoskeletal defects are
so far rare, but their study has provided valuable insight
into the normal function of the cytoskeleton in the
immune system. The fact that defects in a number of
genes are known to give rise to actin-related immunodefi-
ciencies serves to highlight the importance of the cyto-
skeleton in normal immune homeostasis and effector
function. It is therefore highly likely that further genes
will be identified as the cause of actin-related immunode-
ficiencies.
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